The value of homocysteine in osteoporosis secondary to systemic lupus erythematosus
10.3760/cma.j.cn115455-20200507-00572
- VernacularTitle:同型半胱氨酸与系统性红斑狼疮继发性骨质疏松的相关性研究
- Author:
Miqian ZHONG
- From:
Chinese Journal of Postgraduates of Medicine
2021;44(2):123-127
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the relationship between serum homocysteine(Hcy) and osteoporosis in patients with systemic lupus erythematosus (SLE).Methods:A total of 105 SLE patients were selected in Shaoxing Central Hospital from December 2017 to May 2018. According to the risk of osteoporotic fracture, they were divided into two groups: low-risk group(69 patients), middle-high-risk group (36 patients). After anti-osteoporosis treatment for 12 months, the relationship between bone mineral density (BMD), T value and serum Hcy level were analyzed.Results:The level of BMD of both groups increased after treatment, and the difference was statistically significant ( P<0.05). In low-risk group, the T value of lumbar spine increased significantly after treatment ( P<0.05). the T value of neck of femur had an upward trend, but the difference was not statistically significant ( P>0.05). In middle-high-risk group, the T values of lumbar vertebrae and femoral neck were significantly higher after treatment ( P<0.05). There was significant difference in serum Hcy between middle-high-risk group and low-risk group before treatment: (15.42 ± 4.13) μmol/L vs. (13.52 ± 3.12) μmol/L, P<0.05. The level of serum Hcy in both groups decreased after treatment: (12.14 ± 3.17) μmol/L vs. (13.52 ± 3.12) μmol/L, (13.73 ± 3.22) μmol/L vs. (15.42 ± 4.13) μmol/L, and the differences were statistically significant ( P< 0.05). The serum Hcy level was negatively correlated with both bone mineral density and T value ( P<0.05). Positive correlation was observed between serum Hcy level and fracture risk ( P<0.05). Conclusions:Serum Hcy is negatively correlated with osteoporosis in SLE patients and declines significantly after anti-osteoporosis treatment. Hcy is expected to be a promising biomarker for secondary osteoporosis in patients with autoimmune system diseases.
